文献速递细菌感染、耐药与抗菌药物

一项在全州范围内协作质量改进项目以优化无并发症社区获得性肺炎住院患者的抗生素疗程与结局

A Statewide Collaborative Quality Initiative to Improve Antibiotic Duration and Outcomes in Patients Hospitalized With Uncomplicated Community-Acquired Pneumonia.
PubMed 文献 · Clin Infect Dis · 2022-01-01

该前瞻性协作质量改进项目纳入密歇根医院医学会安全联盟41家医院中符合5天抗生素疗程的无并发症社区获得性肺炎住院患者,通过基准比较、最佳实践分享和绩效付费激励促进适宜5天治疗。2017年2月23日至2020年2月5日期间,适宜5±1天疗程比例从22.1%升至45.9%(aOR每季度1.10),30天复合不良事件从18.5%下降(aOR每季度0.98),主要因抗生素相关不良事件减少(aOR每季度0.91)。

要点

  • 适宜5±1天抗生素疗程比例从22.1%升至45.9%(aOR每季度1.10,95%CI 1.07-1.14)。
  • 30天复合不良事件发生于18.5%患者(1166/6319),随时间下降(aOR每季度0.98,95%CI 0.96-0.99)。
  • 抗生素相关不良事件减少(aOR每季度0.91,95%CI 0.87-0.95)。

核心结论

  • 在多样化医院中,参与HMS与无并发症社区获得性肺炎住院患者更适宜的短疗程治疗和更少不良事件相关。

研究设计与样本

  • 前瞻性协作质量改进项目,纳入41家参与密歇根医院医学会安全联盟(HMS)的医院中符合5天抗生素疗程的无并发症社区获得性肺炎住院患者,共6553例。

主要发现

  • 适宜5±1天抗生素疗程比例从22.1%(预测概率20.9%,95%CI 17.2%-25.0%)升至45.9%(预测概率43.9%,95%CI 36.8%-51.2%),aOR每季度1.10(95%CI 1.07-1.14)。
  • 30天复合不良事件(死亡、再入院、急诊就诊和抗生素相关不良事件)发生于18.5%患者(1166/6319),随时间下降(aOR每季度0.98,95%CI 0.96-0.99)。
  • 抗生素相关不良事件下降(aOR每季度0.91,95%CI 0.87-0.95)。

临床怎么用

  • 作者认为,建立具有数据收集和基准比较、最佳实践分享及绩效付费激励的国家或区域协作质量改进项目,可能改善无并发症社区获得性肺炎住院患者的抗生素使用和结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Community-acquired pneumonia (CAP) is a common cause for hospitalization and antibiotic overuse. We aimed to improve antibiotic duration for CAP across 41 hospitals participating in the Michigan Hospital Medicine Safety Consortium (HMS). METHODS: This prospective collaborative quality initiative included patients hospitalized with uncomplicated CAP who qualified for a 5-day antibiotic duration. Between 23 February 2017 and 5 February 2020, HMS targeted appropriate 5-day antibiotic treatment through benchmarking, sharing best practices, and pay-for-performance incentives. Changes in outcomes, including appropriate receipt of 5 ± 1-day antibiotic treatment and 30-day postdischarge composite adverse events (ie, deaths, readmissions, urgent visits, and antibiotic-associated adverse events), were assessed over time (per 3-month quarter), using logistic regression and controlling for hospital clustering. RESULTS: A total of 41 hospitals and 6553 patients were included. The percentage of patients treated with an appropriate 5 ± 1-day duration increased from 22.1% (predicted probability, 20.9% [95% confidence interval: 17.2%-25.0%]) to 45.9% (predicted probability, 43.9% [36.8%-51.2%]; adjusted odds ratio [aOR] per quarter, 1.10 [1.07-1.14]). Thirty-day composite adverse events occurred in 18.5% of patients (1166 of 6319) and decreased over time (aOR per quarter, 0.98 [95% confidence interval: .96-.99]) owing to a decrease in antibiotic-associated adverse events (aOR per quarter, 0.91 [.87-.95]). CONCLUSIONS: Across diverse hospitals, HMS participation was associated with more appropriate use of short-course therapy and fewer adverse events in hospitalized patients with uncomplicated CAP. Establishment of national or regional collaborative quality initiatives with data collection and benchmarking, sharing of best practices, and pay-for-performance incentives may improve antibiotic use and outcomes for patients hospitalized with uncomplicated CAP.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Vaughn VM, Gandhi TN, Hofer TP, et al. A Statewide Collaborative Quality Initiative to Improve Antibiotic Duration and Outcomes in Patients Hospitalized With Uncomplicated Community-Acquired Pneumonia. Clin Infect Dis. 2022. PMID: 34791085. doi:10.1093/cid/ciab950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。